HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a price target of $25.
July 25, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated its Neutral rating on Sage Therapeutics and maintained a price target of $25.
The reiteration of a Neutral rating and maintenance of the $25 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100